Pharmaceutical Market Scope And Analysis

  • Report Code : TIPRE00029839
  • Category : Life Sciences
  • Status : Published
  • No. of Pages : 386
Buy Now

Pharmaceutical Market Scope, Size, and Share by 2031

Buy Now

Pharmaceuticals Market Report Pharmaceuticals Market Size and Share Pharmaceuticals Market Scope and Analysis

Pharmaceuticals Market Report Scope

Report Attribute Details
Market size in 2024 US$ 1,757.78 Billion
Market Size by 2031 US$ 2,840.30 Billion
Global CAGR (2025 - 2031) 7.1%
Historical Data 2021-2023
Forecast period 2025-2031
Segments Covered By Molecule Type
  • Small Molecule
  • Biological and Biosimilar Products
By Indication
  • Metabolic Diseases
  • Cancer
  • Immunology
  • Respiratory Disorder
  • Cardiovascular Disorder
  • Neurology Disorder
  • Rare Disease
By Product
  • Branded
  • Generic
By Type
  • Prescription
  • OTC Drugs
Regions and Countries Covered North America
  • US
  • Canada
  • Mexico
Europe
  • UK
  • Germany
  • France
  • Russia
  • Italy
  • Rest of Europe
Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
South and Central America
  • Brazil
  • Argentina
  • Rest of South and Central America
Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa
Market leaders and key company profiles
  • Johnson Johnson
  • Pfizer Inc
  • Merck Co Inc
  • Eli Lilly and Co
  • Bristol Myers Squibb Co
  • ESTEVE
  • UCB SA
  • Teva Pharmaceutical Industries Ltd
  • Hikma Pharmaceuticals Plc
  • Viatris Inc

    • Pharmaceuticals Market News and Recent Developments

    The Pharmaceuticals Market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. A few of the key developments in the market are listed below:

    • Johnson & Johnson announced that the US Food and Drug Administration (FDA) granted investigational nipocalimab Fast Track Designation (FTD) for the treatment of adult patients with moderate-to-severe Sjögren’s disease (SjD). This follows the therapy's previous receipt of Breakthrough Therapy Designation (BTD) late last year. Currently, there are no approved advanced therapies for treating this disease. (Source: Johnson & Johnson, Company Website, March 2025)
    • Pfizer Inc. announced that the US Food and Drug Administration (FDA) approved the supplemental Biologics License Application (sBLA) for ADCETRIS (brentuximab vedotin) in combination with lenalidomide and a rituximab product. This treatment is for adult patients with relapsed or refractory large B-cell lymphoma (LBCL), including various forms of diffuse large B-cell lymphoma (DLBCL), following two or more lines of systemic therapy. It is intended for those who are not eligible for autologous hematopoietic stem cell transplantation (auto-HSCT) or CAR T-cell therapy. (Source: Pfizer Inc., Company Website, Februay 2025).

    Pharmaceuticals Market Report Coverage and Deliverables

    The "Pharmaceuticals Market Size and Forecast (2021–2031)" report provides a detailed analysis of the market covering below areas:

    • Pharmaceuticals market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
    • Pharmaceuticals market trends, as well as market dynamics such as drivers, restraints, and key opportunities
    • Detailed PEST and SWOT analysis
    • Pharmaceuticals market analysis covering key market trends, global and regional framework, major players, regulations, and recent market developments
    • Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments for the pharmaceuticals market
    • Detailed company profiles